Smith & Nephew SNATS (NYSE:SNN) Downgraded by Wall Street Zen to "Hold"

Key Points

• Wall Street Zen downgraded Smith & Nephew SNATS from “Buy” to “Hold.” Recent analyst views are mixed, but the consensus rating is “Hold,” with an average price target of $31.91.
• The stock opened at $31.16 and has traded between $26.12 and $37.09 over the past 52 weeks.
• Institutional ownership stands at 25.64%; several investors, including Russell Investments Group, increased their holdings in the third quarter.

Smith & Nephew SNATS (NYSE:SNN - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday, Wall Street Zen reports.

Several other equities research analysts also recently issued reports on the company. Zacks Research upgraded Smith & Nephew SNATS from a "strong sell" rating to a "hold" rating in a research report on Tuesday, September 8th. Morgan Stanley lowered shares of Smith & Nephew SNATS from an "overweight" rating to an "equal weight" rating in a research report on Wednesday, September 2nd. Barclays lowered Smith & Nephew SNATS from an "equal weight" rating to an "underweight" rating in a research report on Wednesday, August 5th. BTIG Research started coverage on Smith & Nephew SNATS in a report on Monday, August 31st. They issued a "neutral" rating for the company. Finally, JPMorgan Chase & Co. downgraded shares of Smith & Nephew SNATS from an "overweight" rating to a "neutral" rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $31.91.

Smith & Nephew SNATS Price Performance

Shares of NYSE:SNN opened at $31.16 on Friday. Smith & Nephew SNATS has a fifty-two week low of $26.12 and a fifty-two week high of $37.09. The business's fifty day moving average price is $28.50 and its two-hundred day moving average price is $31.05. The company has a current ratio of 2.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62.

Institutional Trading of Smith & Nephew SNATS

A number of institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. raised its stake in shares of Smith & Nephew SNATS by 62.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 237,366 shares of the medical equipment provider's stock valued at $6,399,000 after acquiring an additional 91,489 shares in the last quarter. Ritholtz Wealth Management increased its position in Smith & Nephew SNATS by 11.4% in the third quarter. Ritholtz Wealth Management now owns 12,094 shares of the medical equipment provider's stock worth $326,000 after buying an additional 1,241 shares during the last quarter. Ethic Inc. increased its stake in shares of Smith & Nephew SNATS by 10.5% in the third quarter. Ethic Inc. now owns 29,168 shares of the medical equipment provider's stock worth $786,000 after buying an additional 2,762 shares during the period. Alps Advisors Inc. raised its stake in Smith & Nephew SNATS by 4.3% during the 3rd quarter. Alps Advisors Inc. now owns 25,790 shares of the medical equipment provider's stock valued at $695,000 after buying an additional 1,054 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC boosted its position in shares of Smith & Nephew SNATS by 15.4% during the third quarter. Ashton Thomas Private Wealth LLC now owns 10,676 shares of the medical equipment provider's stock valued at $288,000 after buying an additional 1,427 shares during the period. 25.64% of the stock is owned by hedge funds and other institutional investors.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company that develops and manufactures products used by healthcare professionals to treat injuries, manage wounds and restore patients' mobility. Founded in 1856 by Thomas James Smith in Hull, England, the company has grown from a pharmacy business into an international healthcare manufacturer.

The company operates across three principal areas: orthopaedics, sports medicine and ear, nose and throat (ENT), and advanced wound management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.